The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Morgan, Andrew P ^a,b   Crowley, James J ^a   Nonneman, Randal J ^a   Quackenbush, Corey R ^a   Miller, Cheryl N ^a   Ryan, Allison K ^a   Bogue, Molly A ^c   Paredes, Sur Herrera ^a,b   Yourstone, Scott ^a,b   Carroll, Ian M ^a,b   Kawula, Thomas H ^a   Bower, Maureen A ^b   Sartor, R Balfour ^a,b   Sullivan, Patrick F ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c JACKSON LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; RNA 16S; BENZODIAZEPINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; ENTEROBACTERIACEAE; FEMALE; IN VITRO STUDY; INTESTINE FLORA; LIQUID CHROMATOGRAPHY; MICROBIOME; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHENOTYPE; STEADY STATE; TANDEM MASS SPECTROMETRY; WEIGHT GAIN; ANIMAL; DRUG EFFECTS;

BACTERIA (MICROORGANISMS); MUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; GASTROINTESTINAL MICROBIOME; MICE; WEIGHT GAIN;

EID: 84919340264     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115225     Document Type: Article

References (58)

1. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223. doi:10.1056/NEJMoa051688.
2. Lieberman JA (2006) Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE). Arch Gen Psychiatry 63: 1069-1072. doi:10.1001/archpsyc.63.10.1069.
3. Foley DL, Morley KI (2011) Systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. Arch Gen Psychiatry 68: 609-616. doi:10.1001/archgenpsychiatry.2011.2.
4. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, et al. (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302: 1765-1773. doi:10.1001/jama.2009.1549.
5. Farwell WR, Stump TE, Wang J, Tafesse E, L'Italien G, et al. (2004) Weight gain and new onset diabetes associated with olanzapine and risperidone. J Gen Intern Med 19: 1200-1205. doi:10.1111/j.1525-1497.2004.40126.x.
6. Wang C, Zhang Z, Sun J, Zhang X, Mou X, et al. (2006) Serum free Fatty acids and glucose metabolism, insulin resistance in schizophrenia with chronic antipsychotics. Biol Psychiatry 60: 1309-1313. doi:10.1016/j.biopsych.2006.03.014.
7. Jeste DV, Gladsjo Ja, Lindamer La, Lacro JP (1996) Medical comorbidity in schizophrenia. Schizophr Bull 22: 413-430.
8. Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J (2008) Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr Res 98: 287-294. doi:10.1016/j.schres.2007.10.005.
9. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, et al. (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 374: 620-627. doi:10.1016/S0140-6736(09)60742-X.
10. Zhang Z-J (2004) Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184: 58-62. doi:10.1192/bjp.184.1.58.
11. Minet-Ringuet J, Even PC, Goubern M, Tomé D, de Beaurepaire R (2006) Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 46: 254-262. doi:10.1016/j.appet.2006.01.008.
12. Albaugh VL, Judson JG, She P, Lang CH, Maresca KP, et al. (2011) Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry 16: 569-581. doi:10.1038/mp.2010.33.
13. Teff KL, Rickels MR, Grudziak J, Fuller C, Nguyen H-L, et al. (2013) Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease. Diabetes 62: 3232-3240. doi:10.2337/db13-0430.
14. Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, et al. (2011) No mental health without physical health. Lancet 377: 611. doi:10.1016/S0140-6736(11)60211-0.
15. Walter J, Ley R (2011) The human gut microbiome: ecology and recent evolutionary changes. Annu Rev Microbiol 65: 411-429. doi:10.1146/annurev-micro-090110-102830.
16. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, et al. (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464: 59-65. doi:10.1038/nature08821.
17. Maurice CF, Haiser HJ, Turnbaugh PJ (2013) Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell 152: 39-50. doi:10.1016/j.cell.2012.10.052.
18. Carroll IM, Threadgill DW, Threadgill DS (2009) The gastrointestinal microbiome: a malleable, third genome of mammals. Mamm Genome 20: 395-403. doi:10.1007/s00335-009-9204-7.
19. Ley RE, Turnbaugh PJ, Klein S, Gordon JI (2006) Microbial ecology: human gut microbes associated with obesity. Nature 444: 1022-1023. doi:10.1038/4441022a.
20. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, et al. (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444: 1027-1031. doi:10.1038/nature05414.
21. Bäckhed F, Manchester JK, Semenkovich CF, Gordon JI (2007) Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA 104: 979-984. doi:10.1073/pnas.0605374104.
22. Turnbaugh PJ, Ridaura VK, Faith JJ, Rey FE, Knight R, et al. (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1: 6ra14. doi:10.1126/scitranslmed.3000322.
23. Cho I, Yamanishi S, Cox L, Methé BA, Zavadil J, et al. (2012) Antibiotics in early life alter the murine colonic microbiome and adiposity. Nature 488: 621-626. doi:10.1038/nature11400.
24. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, et al. (2013) Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science (80-) 341: 1241214. doi:10.1126/science.1241214.
25. Campbell JH, Foster CM, Vishnivetskaya T, Campbell AG, Yang ZK, et al. (2012) Host genetic and environmental effects on mouse intestinal microbiota. ISME J 6: 2033-2044. doi:10.1038/ismej.2012.54.
26. Schloissnig S, Arumugam M, Sunagawa S, Mitreva M, Tap J, et al. (2013) Genomic variation landscape of the human gut microbiome. Nature 493: 45-50. doi:10.1038/nature11711.
27. Zhang C, Li S, Yang L, Huang P, Li W, et al. (2013) Structural modulation of gut microbiota in life-long calorie-restricted mice. Nat Commun 4: 2163. doi:10.1038/ncomms3163.
28. Benson AK, Kelly SA, Legge R, Ma F, Low SJ, et al. (2010) Individuality in gut microbiota composition is a complex polygenic trait shaped by multiple environmental and host genetic factors. Proc Natl Acad Sci USA 107: 18933-18938. doi:10.1073/pnas.1007028107.
29. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999) Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37: 177-193. doi:10.2165/00003088-199937030-00001.
30. Davey KJ, O'Mahony SM, Schellekens H, O'Sullivan O, Bienenstock J, et al. (2012) Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology (Berl) 221: 155-169. doi:10.1007/s00213-011-2555-2.
31. Davey KJ, Cotter PD, O'Sullivan O, Crispie F, Dinan TG, et al. (2013) Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl Psychiatry 3: e309. doi:10.1038/tp.2013.83.
32. Perry PJ, Lund BC, Sanger T, Beasley C (2001) Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol 21: 14-20.
33. Zhang G, Terry A V, Bartlett MG (2007) Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue. J Chromatogr B Anal Technol Biomed Life Sci 858: 276-281. doi:10.1016/j.jchromb.2007.08.007.
34. Simon GM, Cheng J, Gordon JI (2012) Quantitative assessment of the impact of the gut microbiota on lysine epsilon-acetylation of host proteins using gnotobiotic mice. Proc Natl Acad Sci USA 109: 11133-11138. doi:10.1073/pnas.1208669109.
35. Nixon JP, Zhang M, Wang C, Kuskowski MA, Novak CM, et al. (2010) Evaluation of a quantitative magnetic resonance imaging system for whole body composition analysis in rodents. Obesity 18: 1652-1659. doi:10.1038/oby.2009.471.
36. Lundberg DS, Yourstone S, Mieczkowski P, Jones CD, Dangl JL (2013) Practical innovations for high-throughput amplicon sequencing. Nat Methods 10: 999-1002. doi:10.1038/nmeth.2634.
37. Wang Q, Garrity GM, Tiedje JM, Cole JR (2007) Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Env Microbiol 73: 5261-5267. doi:10.1128/AEM.00062-07.
38. Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, et al. (2010) QIIME allows analysis of high-throughput community sequencing data. Nat Methods 7: 335-336. doi:10.1038/nmeth.f.303.
39. Caporaso JG, Bittinger K, Bushman FD, DeSantis TZ, Andersen GL, et al. (2010) PyNAST: a flexible tool for aligning sequences to a template alignment. Bioinformatics 26: 266-267. doi:10.1093/bioinformatics/btp636.
40. Price MN, Dehal PS, Arkin AP (2009) FastTree: computing large minimum evolution trees with profiles instead of a distance matrix. Mol Biol Evol 26: 1641-1650. doi:10.1093/molbev/msp077.
41. Lozupone C, Knight R (2005) UniFrac: a New Phylogenetic Method for Comparing Microbial Communities. Appl Env Microbiol 71: 8228-8235. doi:10.1128/AEM.71.12.8228.
42. Anderson MJ (2001) A new method for non-parametric multivariate analysis of variance. Austral Ecol 26: 32-46.
43. Venables WN, Ripley BD (2002) Modern Applied Statistics with S. Fourth. New York: Springer.
44. Collaborative Cross Consortium (2012) The genome architecture of the Collaborative Cross mouse genetic reference population. Genetics 190: 389-401. doi:10.1534/genetics.111.132639.
45. Fisher RA, Corbett AS, Williams CB (1943) The Relation Between the Number of Species and the Number of Individuals in a Random Sample of an Animal Population. J Anim Ecol 12: 42-58.
46. Chesler EJ, Miller DR, Branstetter LR, Galloway LD, Jackson BL, et al. (2008) The Collaborative Cross at Oak Ridge National Laboratory: developing a powerful resource for systems genetics. Mamm Genome 19: 382-389. doi:10.1007/s00335-008-9135-8.
47. Svenson KL, Gatti DM, Valdar W, Welsh CE, Cheng R, et al. (2012) High-resolution genetic mapping using the Mouse Diversity outbred population. Genetics 190: 437-447. doi:10.1534/genetics.111.132597.
48. Jumpstart Consortium Human Microbiome Project Data Generation Working Group (2012) Evaluation of 16S rDNA-based community profiling for human microbiome research. PLoS One 7: e39315. doi:10.1371/journal.pone.0039315.
49. McCafferty J, Mühlbauer M, Gharaibeh RZ, Arthur JC, Perez-Chanona E, et al. (2013) Stochastic changes over time and not founder effects drive cage effects in microbial community assembly in a mouse model. ISME J 7: 2116-2125. doi:10.1038/ismej.2013.106.
50. Lozupone CA, Stombaugh J, Gonzalez A, Ackermann G, Wendel D, et al. (2013) Meta-analyses of studies of the human microbiota. Genome Res 23: 1704-1714. doi:10.1101/gr.151803.112.
51. Spencer MD, Hamp TJ, Reid RW, Fischer LM, Zeisel SH, et al. (2011) Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140: 976-986. doi:10.1053/j.gastro.2010.11.049.
52. Raman M, Ahmed I, Gillevet PM, Probert CS, Ratcliffe NM, et al. (2013) Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 11: 868-75.e1-3. doi:10.1016/j.cgh.2013.02.015.
53. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, et al. (2012) Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482: 179-185. doi:10.1038/nature10809.
54. Jenkins AJ, Sarconi KM, Raaf HN (1998) Determination of olanzapine in a postmortem case. J Anal Toxicol 22: 605-609.
55. Kristiansen JE (1979) Experiments to illustrate the effect of chlorpromazine on the permeability of the bacterial cell wall. Acta Pathol Microbiol Scand B 87: 317-319.
56. Thorsing M, Klitgaard JK, Atilano ML, Skov MN, Kolmos HJ, et al. (2013) Thioridazine induces major changes in global gene expression and cell wall composition in methicillin-resistant Staphylococcus aureus USA300. PLoS One 8: e64518. doi:10.1371/journal.pone.0064518.
57. Rhee SH, Pothoulakis C, Mayer EA (2009) Principles and clinical implications of the brain-gut-enteric microbiota axis. Nat Rev Gastroenterol Hepatol 6: 306-314. doi:10.1038/nrgastro.2009.35.
58. Leslie WS, Hankey CR, Lean MEJ (2007) Weight gain as an adverse effect of some commonly prescribed drugs: a systematic review. QJM 100: 395-404. doi:10.1093/qjmed/hcm044.